Other News To Note
Wednesday, September 12, 2012
Compugen Ltd., of Tel Aviv, Israel, said mode-of-action studies on protein drug candidate CGEN-15001 demonstrated active suppression of pathogenic immune responses and reestablishment of immune balance by increasing anti-inflammatory mediators and promoting inducible regulatory T cells, considered a promising approach to treat autoimmune disease and cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.